Lung cancer is the leading cause of cancer-related mortality in the United States and is comprised of two main histologic subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Fortunately, advanced drug therapies and genetic testing are making a big difference for many patients and their families. Hear from highly-regarded lung cancer experts, nurse practitioners and patients from across the globe.
Upcoming EventsSee all events
Thursday, October 29, 2020
Immunotherapies have radically changed treatment for non-small cell lung cancer (NSCLC) patients. In fact, the PD-L1/PD-1 blockade is a bona fide breakthrough. What does this fast-moving course of research and treatment mean for lung cancer patients of all persuasions?